Post-protocol therapy and informative censoring in the CANDOR study – Authors' reply

Autor: Usmani, S.Z. Li, C. Obreja, M. Dimopoulos, M.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::0d7bd7a89cb2925c0dfc6ed3499d9422
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3118499

Efficacy and safety of weekly carfilzomib (70 mg/m(2)), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies

Autor: Leleu, X, Beksac, M, Chou, T, Dimopoulos, M, Yoon, SS, Prince, HM, Pour, L, Shelekhova, T, Chari, A, Khurana, M, Zhang, JQ, Obreja, M, Qi, M, Oriol, A, Siegel, D

Publikováno v: LEUKEMIA & LYMPHOMA
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

The regimen of carfilzomib, daratumumab, and dexamethasone (KdD) shows activity in patients with relapsed/refractory multiple myeloma. KdD at the twice-weekly 56 mg/m(2) carfilzomib dose (KdD56) was used in the randomized phase 3 CANDOR study (NCT031

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::252e1c9085858eea5781da29b7947c90
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4000

Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option : a cross-study comparison of the CANDOR and EQUULEUS studies

Autor: Leleu, X., Beksac, M., Chou, T., Dimopoulos, M., Yoon, S.S., Prince, H.M., Pour, L., Shelekhova, T., Chari, A., Khurana, M., Zhang, J., Obreja, M., Qi, M., Oriol, Albert, Siegel, D., Universitat Autònoma de Barcelona

Publikováno v: Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Recercat. Dipósit de la Recerca de Catalunya
instname
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona

The regimen of carfilzomib, daratumumab, and dexamethasone (KdD) shows activity in patients with relapsed/refractory multiple myeloma. KdD at the twice-weekly 56 mg/m2 carfilzomib dose (KdD56) was used in the randomized phase 3 CANDOR study (NCT03158

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::779b523ac619c8875a4d6f63391fce45
http://hdl.handle.net/2072/445092

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study

Autor: Dimopoulos, M. Wang, M. Maisnar, V. Minarik, J. Bensinger, W. Mateos, M.-V. Obreja, M. Blaedel, J. Moreau, P.

Background: In ASPIRE, carfilzomib, lenalidomide, and dexamethasone (KRd) significantly improved progression-free survival (PFS) and response rates versus lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma. Per protocol, p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::4704b845e245ddd10047b657925ac150
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3086008